DexCom, Inc. (DXCM)
|Net Income (ttm)||530.60M|
|Day's Range||550.00 - 561.19|
|52-Week Range||305.63 - 579.00|
|Price Target||544.10 (-3.0%)|
|Est. Earnings Date||Oct 28, 2021|
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LL... [Read more...]
In 2020, DexCom's revenue was $1.93 billion, an increase of 30.54% compared to the previous year's $1.48 billion. Earnings were $493.60 million, an increase of 388.23%.Financial Statements
According to 21 analysts, the average rating for DexCom stock is "Buy." The 12-month stock price forecast is 544.10, which is a decrease of -2.98% from the latest price.
DexCom (DXCM) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Dexcom Expands Time in Range Initiative with Nick Jonas to Help Improve the Lives of People with Diabetes in the UK
LONDON--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ:DXCM), the global leader in continuous glucose monitoring for people with diabetes, today announced the UK launch of its Time in Range Campaign, an awarenes...
Both companies are in industries with strong opportunity ahead.
Investors continue to be optimistic about DexCom (DXCM) owing to its slew of favorable coverage decisions for its G6 CGM System.
Stocks Rebound, But Will Rally Attempt Have Legs? Datadog, Microsoft, Dexcom Show Strength
Stocks rebound, but will rally attempt have legs? Datadog, Microsoft, Dexcom show strength.
Dexcom Schedules Third Quarter 2021 Earnings Release and Conference Call for October 28, 2021 at 4:30 p.m. Eastern Time
SAN DIEGO--(BUSINESS WIRE)--Dexcom Schedules Third Quarter 2021 Earnings Release and Conference Call for October 28, 2021 at 4:30 p.m. Eastern Time.
Their products are better than those of their rivals, and their leads are increasing.
Dexcom's (DXCM) CGM System is expected to simplify diabetes management due to increasing access to the life changing technology.
The stock isn't a household name, but it's generated multibagger returns over the past five years alone.
We think that Dexcom stock currently is a better pick compared to Abbott stock, despite Dexcom being more expensive of the two. Dexcom trades at about 25x trailing revenues, compared to just 5x for Abbott.
Dexcom G6 Continuous Glucose Monitoring System Now Covered in Manitoba for Young People With Type 1 Diabetes
BURNABY, British Columbia--(BUSINESS WIRE)--Dexcom G6 Continuous Glucose Monitoring System now Covered in Manitoba for Young People With Type 1 Diabetes
A few months back we discussed that going by its historical performance Dexcom Stock may continue to rally after a 23% rise in a month. DXCM stock has since rallied 34%, while it is up 11% over the last...
Expanded access to Dexcom's (DXCM) G6 CGM for clients enrolled in NIHB is expected to aid a wider patient pool to better manage their diabetes.
Non-insured Health Benefits Program Now Covers Dexcom G6 Continuous Glucose Monitoring System for Children and Adoles...
BURNABY, British Columbia--(BUSINESS WIRE)--Non-Insured Health Benefits Program now Covers Dexcom G6 CGM System for Children and Adolescents on Intensive Insulin Therapy
A smart monitor company that received FDA approval in 2015 has seen a five-year stock performance that has outperformed the returns of Apple Inc (NASDAQ: AAPL), Alphabet Inc (NASDAQ: GOOG)(NASDAQ: GOOGL...
SAN DIEGO--(BUSINESS WIRE)--Dexcom Announces Upcoming Virtual Conference Presentations
Despite a mixed Q2 2021 result, bullish sentiment is building for Senseonics. Here's why SENS stock can run-up in the future.
U.S. indices bounced off Monday morning's lows as investors weigh weak China retail and production data. Uncertainty around the COVID-19 Delta variant is also weighing on the market.
These companies are still going to be great long-term buys.